NSCIF logo

Nanalysis Scientific Corp. (NSCIF) Hisse Analizi

Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

NSCIF, $ (piyasa değeri 0) fiyatla Technology işi olan Nanalysis Scientific Corp.'i temsil ediyor. Hisse senedi, 9 kantitatif KPI'ya dayalı olarak orta dereceli bir derecelendirme olan 50/100 puan alıyor.

Son analiz: 17 Mar 2026
50/100 AI Puanı

Nanalysis Scientific Corp. (NSCIF) Teknoloji Profili ve Rekabetçi Konumu

CEOSean Krakiwsky
Çalışanlar249
MerkezCalgary, CA
Halka Arz Yılı2020
SektörTechnology

Nanalysis Scientific Corp. specializes in compact NMR spectrometers and MRI equipment, catering to diverse sectors like pharmaceuticals and chemicals. With a global distribution network and a focus on innovative analytical instruments, Nanalysis operates in a competitive technology landscape, balancing growth opportunities with financial challenges.

Veri Kaynağı | Finansal Veriler Kantitatif Analiz NASDAQ Analiz: 17 Mar 2026

Yatırım Tezi

Nanalysis Scientific Corp. presents a compelling investment case centered on its innovative compact NMR technology and diverse market applications. Key value drivers include expanding adoption of compact NMR in industries seeking cost-effective and accessible analytical solutions. The company's growth catalysts involve penetrating new markets, launching advanced software modules, and leveraging its global distribution network. While Nanalysis operates in a high-growth sector, potential risks include negative profit margins (-29.7%), competition from established players, and the need for continuous innovation to maintain its technological edge. Investors should closely monitor the company's ability to improve profitability, expand its customer base, and capitalize on growth opportunities in the analytical instruments market. The company's beta of 0.08 indicates low volatility compared to the overall market.

FMP finansallarına ve nicel analizine dayanmaktadır

Temel Önemli Noktalar

  • Market capitalization of $0.01 billion indicates a small-cap company with potential for growth.
  • Negative P/E ratio of -1.29 reflects current losses, requiring focus on profitability improvements.
  • Gross margin of 27.0% demonstrates the company's ability to generate revenue above the cost of goods sold.
  • Profit margin of -29.7% highlights the need for cost management and revenue growth to achieve profitability.
  • The company operates in the technology sector, specifically within the hardware, equipment, and parts industry, indicating exposure to innovation and technological advancements.

Rakipler & Benzerleri

Güçlü Yönler

  • Innovative compact NMR technology.
  • Diverse customer base across multiple industries.
  • Global distribution network.
  • Integrated software solutions.

Zayıflıklar

  • Negative profit margins.
  • Small market capitalization.
  • Dependence on continuous innovation.
  • Limited brand recognition compared to larger competitors.

Katalizörler

  • Upcoming: Launch of advanced software modules for NMR spectrometers, enhancing data analysis capabilities.
  • Ongoing: Expansion of the global distribution network to penetrate new markets and increase sales.
  • Ongoing: Continuous innovation in compact NMR technology to maintain competitive edge.
  • Ongoing: Strategic partnerships and acquisitions to expand product portfolio and access new technologies.

Riskler

  • Ongoing: Negative profit margins require significant improvement in cost management and revenue growth.
  • Potential: Competition from established players with greater resources and brand recognition.
  • Potential: Technological obsolescence could render existing products less competitive.
  • Potential: Economic downturns could reduce customer spending on analytical instruments.
  • Ongoing: Limited liquidity on the OTC market increases price volatility and trading risks.

Büyüme Fırsatları

  • Expanding Market Penetration: Nanalysis has the opportunity to expand its market penetration by targeting new geographic regions and industries. The global analytical instruments market is projected to reach $75 billion by 2028, driven by increasing demand for advanced analytical solutions. By leveraging its global distribution network and tailoring its products to specific market needs, Nanalysis can increase its market share and revenue growth. Timeline: Ongoing.
  • Product Innovation and Development: Continuous innovation in NMR technology is crucial for Nanalysis to maintain its competitive edge. The company can invest in developing advanced software modules, enhancing the capabilities of its compact NMR spectrometers, and exploring new applications for its technology. This will attract new customers and drive revenue growth. The company should focus on R&D to stay ahead of competitors. Timeline: Ongoing.
  • Strategic Partnerships and Acquisitions: Nanalysis can pursue strategic partnerships and acquisitions to expand its product portfolio, access new technologies, and enter new markets. Collaborating with complementary technology providers and acquiring companies with innovative analytical solutions can accelerate growth and enhance the company's competitive position. Timeline: Ongoing.
  • Focus on Software Solutions: Nanalysis can capitalize on the increasing demand for software-driven analytical solutions by developing advanced software modules and integrating them with its NMR spectrometers. These software solutions can provide enhanced data analysis, automation, and user-friendly interfaces, attracting customers seeking comprehensive analytical solutions. The global market for analytical software is expected to grow significantly. Timeline: Ongoing.
  • Leveraging the RS2D Segment: The RS2D segment, which manufactures cutting-edge electronics components, provides a unique growth opportunity for Nanalysis. By expanding the production and sales of these components to other analytical instrument manufacturers, Nanalysis can diversify its revenue streams and capitalize on the growing demand for precision electronics in the analytical instruments market. Timeline: Ongoing.

Fırsatlar

  • Expanding market penetration in emerging economies.
  • Developing advanced software modules for NMR data analysis.
  • Strategic partnerships and acquisitions.
  • Increasing demand for portable analytical instruments.

Tehditler

  • Competition from established players with greater resources.
  • Technological obsolescence.
  • Economic downturns affecting customer spending.
  • Regulatory changes impacting the analytical instruments market.

Rekabet Avantajları

  • Proprietary compact NMR technology provides a unique selling proposition.
  • Established global distribution network ensures broad market reach.
  • Diverse customer base across various industries reduces dependence on a single sector.
  • Integrated software solutions enhance the value of NMR spectrometers.

NSCIF Hakkında

Nanalysis Scientific Corp., founded to revolutionize NMR technology, develops, manufactures, and sells compact NMR spectrometers and magnetic resonance imaging (MRI) equipment. These instruments cater to a wide array of industries, including pharmaceutical, biotech, chemical, security, food, materials, and education. The company operates through three key segments: Nanalysis, which focuses on the core NMR products; RS2D, specializing in cutting-edge electronics components for analytical instruments; and Corporate, handling overall management and strategy. Nanalysis offers software module packages and provides ongoing monitoring and support services for its NMR technologies. From its headquarters in Calgary, Canada, Nanalysis has expanded its reach through a direct sales force and a global network of distributors. The company's products are used in various applications, such as quality control, research and development, and material analysis. Nanalysis aims to provide accessible and user-friendly NMR solutions, differentiating itself from traditional, larger-scale NMR systems. The company's growth strategy involves continuous innovation in NMR technology, expanding its product portfolio, and penetrating new markets. Nanalysis faces competition from established players in the analytical instruments market, requiring ongoing investment in research and development to maintain its competitive edge.

Ne Yaparlar

  • Develops and manufactures compact nuclear magnetic resonance (NMR) spectrometers.
  • Creates magnetic resonance imaging (MRI) equipment.
  • Offers solutions for pharmaceutical, biotech, chemical, and other industries.
  • Provides software module packages for data analysis and automation.
  • Manufactures electronics components for precision analytical instruments.
  • Offers monitoring and support services for NMR technologies.
  • Sells products directly and through a global distributor network.

İş Modeli

  • Sells compact NMR spectrometers and MRI equipment to various industries.
  • Generates revenue from software module packages and support services.
  • Manufactures and sells electronics components for analytical instruments.
  • Distributes products through a direct sales force and a global network of distributors.

Sektör Bağlamı

Nanalysis Scientific Corp. operates in the analytical instruments market, a segment of the broader technology sector. The industry is characterized by continuous innovation, driven by advancements in technology and increasing demand for precise analytical solutions. Key trends include the adoption of compact and portable instruments, growing applications of NMR technology in various industries, and increasing demand for software-driven analytical solutions. Competitors include established players offering traditional NMR systems and other analytical instruments. Nanalysis aims to differentiate itself through its focus on compact NMR technology, user-friendly solutions, and a diverse range of applications.

Kilit Müşteriler

  • Pharmaceutical companies using NMR for drug discovery and quality control.
  • Biotech firms employing NMR for protein analysis and research.
  • Chemical companies utilizing NMR for material analysis and reaction monitoring.
  • Educational institutions using NMR for teaching and research purposes.
AI Güveni: 70% Güncellendi: 17 Mar 2026

Finansallar

Grafik & Bilgi

Nanalysis Scientific Corp. (NSCIF) hisse senedi fiyatı: Price data unavailable

Son Haberler

Analist Konsensüsü

Fikir Birliği Derecelendirmesi

NSCIF için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.

Fiyat Hedefleri

NSCIF için Wall Street fiyat hedefi analizi.

MoonshotScore

50/100

Bu puan ne anlama geliyor?

MoonshotScore, NSCIF'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.

Yönetim: Sean Krakiwsky

CEO

Sean Krakiwsky serves as the CEO of Nanalysis Scientific Corp. His background includes extensive experience in managing and growing technology companies. He has a proven track record in strategic planning, product development, and market expansion. Prior to joining Nanalysis, Krakiwsky held leadership positions in various technology firms, where he focused on driving innovation and increasing shareholder value. His expertise spans across multiple areas, including sales, marketing, and operations.

Sicil: Under Sean Krakiwsky's leadership, Nanalysis Scientific Corp. has focused on expanding its global presence and enhancing its product offerings. Key milestones include the development of advanced software modules for NMR spectrometers and the establishment of strategic partnerships to penetrate new markets. Krakiwsky has also overseen efforts to improve operational efficiency and reduce costs. He manages 249 employees.

NSCIF OTC Piyasa Bilgileri

The OTC Other tier represents the lowest tier of the OTC market, indicating that Nanalysis Scientific Corp. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not provide comprehensive financial disclosures. Investing in OTC Other stocks carries higher risks compared to stocks listed on major exchanges due to the lack of regulatory oversight and transparency. These stocks are often more speculative and may be subject to wider price fluctuations.

  • OTC Katmanı: OTC Other
  • Açıklama Durumu: Unknown
Likidite: Liquidity for NSCIF on the OTC market is likely limited, given its listing on the OTC Other tier. This typically translates to lower trading volumes and potentially wider bid-ask spreads, making it more difficult to buy or sell shares quickly and at desired prices. Investors may experience price slippage when executing trades, especially for larger orders. The low liquidity also increases the stock's volatility and susceptibility to price manipulation.
OTC Risk Faktörleri:
  • Limited financial disclosure increases information asymmetry.
  • Low trading volume and liquidity can lead to price volatility.
  • Higher risk of fraud or manipulation due to less regulatory oversight.
  • Potential for delisting or trading suspension.
  • Difficulty in obtaining accurate and timely information about the company.
Durum Tespiti Kontrol Listesi:
  • Verify the company's registration and legal standing.
  • Obtain and review available financial statements.
  • Assess the company's management team and their track record.
  • Research the company's industry and competitive landscape.
  • Evaluate the company's business model and revenue streams.
  • Understand the risks associated with investing in OTC stocks.
  • Consult with a financial advisor before making any investment decisions.
Meşruiyet Sinyalleri:
  • The company develops and manufactures physical products (NMR spectrometers and MRI equipment).
  • Nanalysis Scientific Corp. has a global distribution network, suggesting established operations.
  • The company serves diverse industries, indicating a broad customer base.
  • The company has been in operation for several years, suggesting some level of stability.
  • The company has a CEO and management team in place, indicating organizational structure.

Yatırımcılar Nanalysis Scientific Corp. (NSCIF) Hakkında Ne Soruyor

NSCIF için değerlendirilmesi gereken temel faktörler nelerdir?

Nanalysis Scientific Corp. (NSCIF) şu anda yapay zeka skoru 50/100, orta puanı gösteriyor. Temel güçlü yan: Innovative compact NMR technology.. İzlenmesi gereken birincil risk: Ongoing: Negative profit margins require significant improvement in cost management and revenue growth.. Bu bir finansal tavsiye değildir.

NSCIF MoonshotScore'u nedir?

NSCIF şu anda MoonshotScore'da 50/100 (Derece C) alıyor, bu da orta derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.

NSCIF verileri ne sıklıkla güncellenir?

NSCIF fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.

Analistler NSCIF hakkında ne diyor?

NSCIF için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.

NSCIF'a yatırım yapmanın riskleri nelerdir?

NSCIF için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Ongoing: Negative profit margins require significant improvement in cost management and revenue growth.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.

NSCIF'ın P/E oranı nedir?

NSCIF için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için NSCIF'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.

NSCIF aşırı değerli mi, yoksa düşük değerli mi?

Nanalysis Scientific Corp. (NSCIF)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.

NSCIF'ın temettü verimi nedir?

Nanalysis Scientific Corp. (NSCIF) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.

Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.

Resmi Kaynaklar

Analiz güncellendi AI Puanı günlük olarak yenilenir
Veri Kaynakları ve Metodoloji
Piyasa verileri Financial Modeling Prep ve Yahoo Finance tarafından sağlanmaktadır. AI analizi Stock Expert AI tescilli algoritmaları ile yapılmaktadır. Teknik göstergeler endüstri standardı hesaplamalarla üretilmektedir. Son güncelleme: .

Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.

Analiz Notları
  • AI analysis is pending, limiting the availability of analyst consensus and detailed financial analysis.
  • OTC market listing introduces higher risks and limited information compared to major exchanges.
  • Financial data is based on available information and may not be comprehensive.
Veri Kaynakları

Popüler Hisseler